Analysts on Wall Street project that Eli Lilly (LLY) will announce quarterly earnings of $6.99 per share in its forthcoming report, representing an increase of 31.4% year over year. Revenues are projected to reach $17.87 billion, increasing 32.1% from the same quarter last year.The consensus EPS estimate for the quarter has been revised 8.6% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this ti ...

Core Insights - Financial giants are showing a bullish sentiment towards Eli Lilly and Co, with 47% of traders being bullish and 29% bearish based on options trading analysis [1] - The predicted price range for Eli Lilly and Co is between $720.0 and $1580.0, indicating significant interest from major players [2] - The average open interest for options stands at 224.91, with a total volume of 1,733.00, reflecting active trading in the past month [3] Options Activity - The largest options trades include a bullish sweep call with a total trade value of $967.9K at a strike price of $1160.00, indicating strong bullish sentiment [6] - Other notable trades include bearish calls with varying strike prices, showcasing mixed sentiments among traders [6] Company Overview - Eli Lilly and Co specializes in neuroscience, cardiometabolic, cancer, and immunology, with key products including Verzenio, Mounjaro, and Taltz [7] - Analysts have set an average price target of $1205.5 for Eli Lilly and Co, reflecting positive expectations for the stock [8] Market Performance - The current trading volume for Eli Lilly is 709,068, with the stock price up by 0.99% to $1089.16, indicating a stable market position [10] - Analysts from Guggenheim maintain a Buy rating with a target price of $1161, while UBS has adjusted its target price to $1250, reflecting confidence in the company's future performance [10]

Company Overview - Eli Lilly and Co is a pharmaceutical company focusing on neuroscience, cardiometabolic diseases, cancer, and immunology. Key products include Verzenio for cancer, Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic conditions, and Taltz and Olumiant for immunology [8]. Current Market Status - The current market price of Eli Lilly (LLY) is $1,069.3, reflecting a decrease of 0.73%. The stock has a trading volume of 1,133,591. RSI indicators suggest that the stock may be approaching overbought conditions. The next earnings report is expected in 21 days [10]. - Market experts have issued ratings for Eli Lilly, with a consensus target price set at $1,250. An analyst from UBS has downgraded the stock to a Buy rating with the same price target [9]. Options Trading Insights - Recent options trading activity indicates a bearish sentiment among large investors, with 45% of trades being bearish and 35% bullish. A total of 120 uncommon options trades were detected, with 39 puts amounting to $1,794,386 and 81 calls totaling $4,052,883 [2][3]. - The significant investors are targeting a price range for Eli Lilly between $610.0 and $1,660.0 over the past three months [3]. - The mean open interest for Eli Lilly options trades is 387.99, with a total volume of 2,219.00 [4].

Company Overview - Eli Lilly and Company (LLY) has a market cap of $1 trillion and is a leading global research-based pharmaceutical company, founded in 1876 and headquartered in Indianapolis, Indiana. The company offers a wide range of prescription medicines, including treatments for type 2 diabetes, weight management, cancer, autoimmune conditions, and established insulin therapies [1] Earnings Expectations - Analysts anticipate Eli Lilly to report Q4 earnings of $7.47 per share, representing a 40.4% increase from $5.32 per share in the same quarter last year. The company has surpassed Wall Street's EPS estimates in three of the last four quarters [2] - For fiscal 2025, the expected EPS is $23.95, an 84.4% increase from $12.99 in fiscal 2024, with a projected rise to $33.59 in fiscal 2026, reflecting a 40.3% annual growth [3] Stock Performance - Eli Lilly's stock has increased by 35.1% over the past 52 weeks, outperforming the S&P 500 Index's 19.7% gains and the S&P 500 Healthcare Sector SPDR's 12.7% returns during the same period [4] Strategic Developments - On January 7, Eli Lilly's shares rose by 3.3% following the announcement of a strategic partnership with Nimbus Therapeutics to develop an oral obesity treatment, which includes a $55 million upfront payment and potential milestone payments of up to $1.3 billion. Additionally, the company is in advanced talks to acquire Ventyx Biosciences for over $1 billion, aimed at enhancing its drug portfolio and reinforcing its position in the weight-loss therapeutics market [5] Analyst Consensus - The consensus opinion on Eli Lilly stock is "Strong Buy," with 22 out of 27 analysts recommending a "Strong Buy," two suggesting a "Moderate Buy," and three advising a "Hold." The average analyst price target for Eli Lilly is $1,161.76, indicating a potential upside of 7.5% from current price levels [6]

Company Overview - Eli Lilly is a pharmaceutical company focusing on neuroscience, cardiometabolic diseases, cancer, and immunology, with key products including Verzenio, Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, Humulin, Taltz, and Olumiant [11]. Market Sentiment - Recent options trading indicates a bearish sentiment among large investors, with 42% bearish and 39% bullish positions noted [3]. - A total of 33 uncommon options trades were identified, with 9 puts amounting to $1,005,471 and 24 calls totaling $1,892,620 [2][3]. Options Analysis - The average open interest for Eli Lilly options is 420.12, with a total volume of 954.00, indicating significant trading activity [5]. - The price target for Eli Lilly based on recent options activity is projected between $500.0 and $1600.0 [4]. Expert Ratings - Analysts have provided an average target price of $1,222.67 for Eli Lilly, with individual ratings from Wells Fargo, BMO Capital, and B of A Securities maintaining target prices of $1,200 and $1,268 [12][13]. Current Stock Performance - Eli Lilly's stock price is currently at $1,064.19, reflecting a decrease of 0.98%, with upcoming earnings expected in 34 days [15].

Core Insights - Financial institutions are showing a bullish sentiment towards Eli Lilly, with 41% of traders being bullish and 32% bearish, indicating a strong interest in the stock [1] - The predicted price range for Eli Lilly over the last three months is between $730.0 and $1200.0, suggesting significant market expectations [2] - Analysts have set an average target price of $1174.2 for Eli Lilly, with various firms maintaining or upgrading their ratings [9][10] Options Activity - A total of 46 unusual trades were identified for Eli Lilly, with 41 being calls valued at $2,414,792 and 5 puts valued at $616,686, reflecting a preference for bullish positions [1] - The mean open interest for Eli Lilly options trades is 648.68, with a total volume of 1,068.00, indicating active trading [3] - Noteworthy options activity includes a mix of bullish and bearish trades, with significant volumes and varying strike prices [7] Company Overview - Eli Lilly focuses on neuroscience, cardiometabolic diseases, cancer, and immunology, with key products including Verzenio, Mounjaro, and Taltz [8] - The stock is currently trading at $1059.99, reflecting a slight increase of 0.03%, with an anticipated earnings release in 73 days [12]

Core Insights - Eli Lilly (LLY) is expected to report quarterly earnings of $6.02 per share, reflecting a year-over-year increase of 410.2% [1] - Revenue projections stand at $16.01 billion, indicating a 40% increase from the same quarter last year [1] - The consensus EPS estimate has been adjusted upward by 0.3% over the past 30 days, showing analysts' reassessment of their projections [1][2] Revenue Estimates - Analysts predict 'Net Sales- Cyramza (Ramucirumab /IMC-1121B)' will reach $237.79 million, a year-over-year change of +0.8% [4] - 'Net Sales- Humulin' is estimated at $180.73 million, reflecting a decline of -12.7% year over year [4] - 'Net Sales- Humalog' is projected at $512.59 million, indicating a decrease of -4.1% from the previous year [4] Additional Sales Projections - 'Net Sales- Forteo' is expected to be $96.63 million, down -18.2% year over year [5] - 'Net Sales- Cyramza (Ramucirumab /IMC-1121B)- US' is forecasted at $107.96 million, suggesting a +1.4% change year over year [5] - 'Net Sales- International- Humalog' is estimated at $212.55 million, reflecting a +0.8% change from the year-ago quarter [5] Geographic Revenue Insights - 'Net Sales- International- Forteo' is projected at $40.97 million, indicating a -11.7% change year over year [6] - 'Net Sales- Humulin- US' is expected to reach $126.25 million, down -15.8% from the previous year [6] - 'Geographic Revenue- United States' is forecasted to be $11.13 billion, suggesting a +42.5% year-over-year increase [7] Market Performance - Over the past month, Lilly shares have increased by +13.9%, outperforming the Zacks S&P 500 composite's +2.5% change [8] - Based on its Zacks Rank 3 (Hold), LLY is expected to perform in line with the overall market in the upcoming period [8]

Core Insights - Investors are showing a bullish stance on Eli Lilly (NYSE: LLY), with significant options trading activity indicating potential upcoming movements in the stock [1] - The overall sentiment among large traders is mixed, with 48% bullish and 35% bearish positions noted [2] - Major market movers are focusing on a price range between $400.0 and $1200.0 for Eli Lilly over the past three months [3] Options Trading Activity - A total of 56 uncommon options trades were identified for Eli Lilly, with 11 puts totaling $538,941 and 45 calls amounting to $3,230,363 [2] - The mean open interest for Eli Lilly options trades today is 739.38, with a total volume of 5,459.00 [4] Price Targets and Analyst Ratings - Recent analyst ratings for Eli Lilly show an average target price of $967.67, with varying opinions from different analysts [12] - A downward revision to a Hold rating was made by Berenberg, adjusting the price target to $830, while JP Morgan and Morgan Stanley maintain Overweight ratings with targets of $1050 and $1023 respectively [13] Company Overview - Eli Lilly is a pharmaceutical company focusing on neuroscience, cardiometabolic diseases, cancer, and immunology, with key products including Verzenio, Mounjaro, and Jardiance [11]

Core Viewpoint - Analysts expect Eli Lilly (LLY) to report quarterly earnings of $5.61 per share, reflecting a year-over-year increase of 43.1%, with revenues projected at $14.75 billion, up 30.5% from the previous year [1] Earnings Projections - The consensus EPS estimate has been revised downward by 1.5% in the past 30 days, indicating a reassessment by analysts [1][2] Key Metrics Forecast - Analysts predict 'Net Sales- Cyramza' at $246.20 million, a decrease of 1.1% year-over-year [4] - 'Net Sales- Humulin' is expected to be $206.10 million, down 7.8% year-over-year [4] - 'Net Sales- Humalog' is projected at $609.52 million, reflecting a decline of 3.5% from the previous year [4] - 'Net Sales- Forteo' is estimated at $62.76 million, down 10.2% year-over-year [5] - 'Net Sales- International-Forteo' is forecasted at $34.28 million, a decrease of 11% [5] - 'Net Sales- Cyramza (ROW)' is expected to reach $130.32 million, down 1.9% year-over-year [6] - 'Net Sales- Emgality (ROW)' is projected at $42.01 million, indicating a significant decline of 22.8% [6] - 'Net Sales- International-Alimta' is estimated at $17.05 million, down 20.3% from the previous year [6] - 'Net Sales- US-Humulin' is expected to be $154.98 million, down 8.5% year-over-year [7] - 'Net Sales- Emgality (US)' is projected at $135.67 million, reflecting a decrease of 1.4% [7] - 'Net Sales- US-Humalog' is estimated at $412.17 million, down 5.2% year-over-year [7] - 'Net Sales- US-Forteo' is expected to reach $28.73 million, indicating a decline of 8.8% [8] Stock Performance - Over the past month, shares of Lilly have returned -2.4%, contrasting with the Zacks S&P 500 composite's +0.6% change [8]

Core Insights - Eli Lilly reported a revenue of $12.73 billion for the quarter ended March 2025, marking a 45.2% increase year-over-year, with an EPS of $3.34 compared to $2.58 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $12.62 billion by 0.86%, while the EPS fell short of the consensus estimate of $3.52 by 5.11% [1] Financial Performance - Key metrics indicate that Eli Lilly's shares have returned +9.9% over the past month, contrasting with a -0.7% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3] Sales Breakdown - Verzenio in the U.S. generated net sales of $657.60 million, below the average estimate of $720.57 million, reflecting a year-over-year increase of 3% [4] - Neuroscience products in the U.S. achieved net sales of $189.30 million, slightly above the average estimate of $188.66 million, with a year-over-year growth of 16% [4] - Geographic revenue from the U.S. reached $8.49 billion, slightly below the $8.50 billion estimate, representing a 49.1% year-over-year increase [4] - Humalog's net sales were $335.10 million, below the average estimate of $361.22 million, showing a year-over-year decline of 1% [4] - Cyramza's total net sales were $224.90 million, slightly below the estimate of $227.45 million, with a year-over-year decrease of 2.2% [4] - Humulin's net sales were $173.20 million, significantly below the estimate of $203.01 million, reflecting a 16% year-over-year decline [4] - Forteo's net sales were $66.60 million, exceeding the average estimate of $50.84 million, with an 8.7% year-over-year increase [4] - Erbitux's net sales were $149 million, slightly above the estimate of $146.04 million, indicating a 3% year-over-year increase [4] - Alimta's net sales were $28.20 million, significantly below the estimate of $46.13 million, showing a 59.4% year-over-year decline [4] - Other pharmaceuticals generated net sales of $212.90 million, slightly below the estimate of $213.18 million, reflecting a 12% year-over-year decline [4] - Oncology products achieved net sales of $1.95 billion, below the average estimate of $2.07 billion, with a year-over-year increase of 7.6% [4]